Comera Life Sciences (CMRA) Competitors $0.0002 0.00 (0.00%) As of 04/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock CMRA vs. SCPS, EVLO, GNCAQ, GNCA, ARDS, STAB, CALA, AMPE, EFTR, and ONCSQShould you be buying Comera Life Sciences stock or one of its competitors? The main competitors of Comera Life Sciences include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Calithera Biosciences (CALA), Ampio Pharmaceuticals (AMPE), eFFECTOR Therapeutics (EFTR), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry. Comera Life Sciences vs. Scopus BioPharma Evelo Biosciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Calithera Biosciences Ampio Pharmaceuticals eFFECTOR Therapeutics OncoSec Medical Comera Life Sciences (NASDAQ:CMRA) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Does the MarketBeat Community believe in CMRA or SCPS? Scopus BioPharma received 2 more outperform votes than Comera Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperformComera Life SciencesN/AN/AScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo Votes Which has stronger earnings and valuation, CMRA or SCPS? Scopus BioPharma has lower revenue, but higher earnings than Comera Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$1.00M0.01-$18MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Does the media refer more to CMRA or SCPS? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral Scopus BioPharma Neutral Is CMRA or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A Scopus BioPharma N/A N/A N/A Which has more volatility and risk, CMRA or SCPS? Comera Life Sciences has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. SummaryComera Life Sciences and Scopus BioPharma tied by winning 2 of the 4 factors compared between the two stocks. Get Comera Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRA vs. The Competition Export to ExcelMetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6,000.00$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.31%P/E RatioN/A6.9521.9417.82Price / Sales0.01231.01380.9497.68Price / CashN/A65.6738.2634.64Price / BookN/A5.936.453.98Net Income-$18M$143.22M$3.22B$247.81M7 Day PerformanceN/A4.28%5.85%3.19%1 Month PerformanceN/A-13.11%-9.55%-7.70%1 Year PerformanceN/A-8.51%11.83%1.49% Comera Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9,000.00N/A0.00120Options VolumeNews CoverageGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastNews CoverageARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020CALACalithera BiosciencesN/A$0.00-40.0%N/A-80.0%$3,000.00N/A0.0060Analyst ForecastNews CoverageGap DownAMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.6%$2,000.00N/A0.0020Analyst ForecastNews CoverageEFTReFFECTOR TherapeuticsN/A$0.00flatN/A-100.0%$1,000.00$3.55M0.0010ONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040 Related Companies and Tools Related Companies SCPS Competitors EVLO Competitors GNCAQ Competitors GNCA Competitors ARDS Competitors STAB Competitors CALA Competitors AMPE Competitors EFTR Competitors ONCSQ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMRA) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMRA Stock Free CMRA Stock Alerts